Practice of HER-2 immunohistochemistry in breast carcinoma in Austria (Q39946651)

15 September 2017

Practice of HER-2 immunohistochemistry in breast carcinoma in Austria (English)

1 reference

15 September 2017

1 reference

0 references

1 reference

A Reiner-Concin

1

1 reference

15 September 2017

P Regitnig

2

1 reference

15 September 2017

H P Dinges

3

1 reference

15 September 2017

G Höfler

4

1 reference

15 September 2017

S Lax

5

1 reference

15 September 2017

E Müller-Holzner

6

1 reference

15 September 2017

P Obrist

7

1 reference

15 September 2017

M Rudas

8

1 reference

15 September 2017

28 August 2008

1 reference

Pathology Oncology Research

15 September 2017

1 reference

15 September 2017

14

1 reference

15 September 2017

3

1 reference

15 September 2017

253-259

1 reference

https://scigraph.springernature.com/pub.10.1007/s12253-008-9079-z

15 September 2017

0 references

cites work

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12253-008-9079-Z

Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer

21 January 2018

1 reference

12 December 2020

HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.

1 reference

12 December 2020

Variability of immunohistochemical reactivity on stored paraffin slides

1 reference

12 December 2020

When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer

1 reference

12 December 2020

Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message

1 reference

12 December 2020

Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.

1 reference

12 December 2020

The use of cell line standards to reduce HER-2/neu assay variation in multiple European cancer centers and the potential of automated image analysis to provide for more accurate cut points for predicting clinical response to trastuzumab

1 reference

12 December 2020

Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization

1 reference

12 December 2020

HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials

1 reference

12 December 2020

Assessment of HER-2/neu Status in Breast Cancer

1 reference

12 December 2020

Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries

1 reference

12 December 2020

Interobserver reproducibility of immunohistochemical HER-2/neu assessment in human breast cancer: an update from INQAT round III.

1 reference

12 December 2020

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

1 reference

12 December 2020

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

1 reference

12 December 2020

Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of A

1 reference

12 December 2020

The Measurement of Observer Agreement for Categorical Data

1 reference

12 December 2020

Best Practice No 176: Updated recommendations for HER2 testing in the UK

1 reference

12 December 2020

Current perspectives on HER2 testing: a review of national testing guidelines

1 reference

12 December 2020

Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.

1 reference

12 December 2020

HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma

1 reference

12 December 2020

10.1007/S12253-008-9079-Z

Identifiers

DOI

1 reference

15 September 2017

1 reference